Arca
Skip to content

Tuberculosis

Drug research and approvals for tuberculosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 154 studies of tuberculosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 8 approved and 22 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 154
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 8
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 154 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

16 approved, 31 in phase 3, 34 in phase 2, 16 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Isoniazid, Rifampin, Pyrazinamide, Rifapentine, Ethambutol, Bedaquiline, Delamanid, Pretomanid, Rifabutin, Protionamide, Cycloserine, Capreomycin, Streptomycin, Ethionamide, Aminosalicylic acid, Rifamycin

Moxifloxacin
Phase 3 Topoisomerase IV inhibitor
Levofloxacin anhydrous
Phase 3 DNA gyrase inhibitor
Linezolid
Phase 3 Bacterial 70S ribosome inhibitor
Clofazimine
Phase 3 DNA inhibitor
Cholecalciferol
Phase 3 Vitamin D receptor agonist
Efavirenz
Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Pyridoxine
Phase 3 Supplement
Doxycycline anhydrous
Phase 3 Matrix metalloproteinase 7 inhibitor
Lamivudine
Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Nevirapine
Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Gatifloxacin
Phase 3 DNA gyrase inhibitor
Kanamycin
Phase 3 Bacterial 70S ribosome inhibitor
Tuberculin
Phase 3
Abacavir
Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Didanosine
Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Meloxicam
Phase 3 Cyclooxygenase-2 inhibitor
Zidovudine
Phase 3 Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Ergocalciferol
Phase 3 Vitamin D receptor agonist
Prednisone
Phase 3 Glucocorticoid receptor agonist
Sulfamethoxazole
Phase 3 Bacterial dihydropteroate synthase inhibitor
Trimethoprim
Phase 3 Bacterial dihydrofolate reductase inhibitor
Clarithromycin
Phase 3 Bacterial 70S ribosome inhibitor
Sitafloxacin anhydrous
Phase 3 Bacterial DNA gyrase inhibitor
Retinol
Phase 3
Folic acid
Phase 3
Niacin
Phase 3
Zinc ion
Phase 3

Showing the 30 furthest along of 81 in trials.

How Its Trials Ended

1,403 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 319 whose ending is known, 61% met their primary endpoint, 14% missed it and 25% stopped early.

  • Completed, result not reported59642%
  • Ongoing27420%
  • Status unknown21415%
  • Met its primary endpoint19314%
  • Stopped: other or unclear504%
  • Missed its primary endpoint463%
  • Stopped: enrollment or feasibility171%
  • Stopped: lack of efficacy60%
  • Stopped: sponsor or business decision30%
  • Stopped: safety20%
  • Stopped: funding20%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Feb 27, 2026Assessment of safety and accuracy of cy-tb, a newtuberculosis-specific skin testCy-tb/siiltibcy (RDESAT-6/RCFP-10)Research Institute Of The Mcgill University Health CentrePending
Oct 31, 2024Study 38 - phase 2c clinical trial of novel, short-course regimens for the treatment of pulmonary tuberculosis: crush-tb (combination regimens for shortening…bedaquiline/ delamanid/ moxifloxacin/ rifabutinResearch Institute Of The Mcgill University Health CentreOngoing
Oct 8, 2024Sstarlet: shorter and safer treatment regimens for latent tbRifapentine / levofloxacin / rifampin / bedaquilineResearch Institute Of The Mcgill University Health CentreOngoing
Aug 10, 2021Six weeks of daily rifapentine vs. a comparator arm of 12-16 week rifamycin-based treatment of latent m. tuberculosis infection: assessment of safety,…RifapentineResearch Institute Of The Mcgill University Health CentreOngoing
Jul 4, 20192r2: higher dose rifampin for 2 months vs standard dose rifampin for latent tb:a 3-arm randomized trialRifampinResearch Institute Of The Mcgill University Health CentreOngoing
Jan 21, 2016Taima tb 3hp study: acceptability and completion rates of a new 12 dose treatment (3 month) compared to the standard treatment for latent tb infection treatmentRifapentineOttawa Hospital Research InstituteClosed

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 30
Jul 28, 2025SirturoAs part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with…Janssen Research & Development, LLCApproved
May 27, 2020SirturoSIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and…Janssen Research & Development, LLCApproved
Aug 14, 2019PretomanidPretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary…Global Alliance for TB Drug DevelopmentApproved
Aug 9, 2019SirturoSIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric…Janssen Research & Development, LLCApproved
Dec 28, 2012SirturoPart of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).Janssen Research & Development, LLCApproved
Jun 22, 1998PriftinTreatment of pulmonary tuberculosis.Hoechst Marion RousselApproved
Jun 30, 1994Paser GranulesTreatment of tuberculosisJacobus Pharmaceutical CompanyApproved
May 31, 1994RifaterShort-course treatment of tuberculosis.Hoechst Marion RousselApproved
Jan 26, 2026SorfequilineTreatment of tuberculosisTB AllianceDesignated
Apr 14, 2025SudapyridineTreatment of tuberculosisShanghai Jiatan Pharmatech Co., LtdDesignated
Nov 6, 2023Alpibectir and ethionamide fixed-dose combination drugTreatment of tuberculosisBioversys SASDesignated
Dec 1, 20205-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,…Treatment of TuberculosisPAI Life Sciences Inc.Designated
Dec 23, 2019Mycobacterium vaccaeTreatment of TuberculosisImmunitor Inc.Designated
Mar 15, 20182-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-…Treatment of Tuberculosis (TB)LMU Klinikum AöRDesignated
Sep 26, 2017Nitric oxideTreatment of non-tuberculosis mycobacterial (NTM) infectionsAdvanced Inhalation Therapies Ltd.Designated

Medicines Authorised in the EU

Newest first
Jan 13, 2025SiiltibcyMycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10)Serum Life Science Europe GmbHEMA ↗
Jul 31, 2020Dovprela (previously Pretomanid FGK)Pretomanid · orphanViatris Healthcare LimitedEMA ↗
Apr 27, 2014DeltybaDelamanidOtsuka Novel Products GmbHEMA ↗
Mar 5, 2014SirturoBedaquilineEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.